Marinus Pharmaceuticals, Inc. (MRNS)
收市後：
| 前收市價 | 1.4400 |
| 開市 | 1.4400 |
| 買盤 | 1.4300 x 2200 |
| 賣出價 | 1.4600 x 5100 |
| 今日波幅 | 1.3900 - 1.4600 |
| 52 週波幅 | 1.1100 - 11.2600 |
| 成交量 | |
| 平均成交量 | 1,741,572 |
| 市值 | 79.101M |
| Beta 值 (5 年，每月) | 0.89 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -2.6300 |
| 業績公佈日 | 2024年5月09日 - 2024年5月13日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 8.80 |
ZacksMarinus (MRNS) Down 83% on Lead Drug Falling Short in Seizure Study
Interim results from a late-stage study show that Marinus' (MRNS) ganaxolone failed to meet the pre-specified stopping criteria in patients with refractory status epilepticus.
InvestorPlaceBiotech on a Budget: 7 Stocks Under $10 With Huge Potential
The broader medical therapeutic sector is already volatile so it stands to reason in some sense to consider under-$10 biotech stocks. Imagine you acquired shares of a popular, richly priced enterprise, only for the underlying security to suffer due to a poor clinical result. And poor results can happen to anybody, big or small. Indeed, the prospect of being on the wrong end of a giant killing adds significant risk to market participants. So, as a calculated approach, since you’re going to be tak
ZacksDo Options Traders Know Something About Marinus (MRNS) Stock We Don't?
Investors need to pay close attention to Marinus (MRNS) stock based on the movements in the options market lately.
